A number of investment brokers have recently updated their price targets on shares of ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD). According to the latest broker reports outstanding on Monday 9th of May, 0 analysts have a rating of “strong buy”, 0 analysts “buy”, 0 analysts “neutral”, 0 analysts “sell” and 0 analysts “strong sell”.

Most recent broker ratings

05/03/2016 – ACADIA Pharmaceuticals Inc. was downgraded to “market perform” by analysts at Leerink Swann. They now have a USD 35 price target on the stock.

05/02/2016 – ACADIA Pharmaceuticals Inc. had its “outperform” rating reiterated by analysts at Cowen. They now have a USD 41 price target on the stock.

05/02/2016 – ACADIA Pharmaceuticals Inc. had its “overweight” rating reiterated by analysts at Piper Jaffray. They now have a USD 44 price target on the stock.

03/30/2016 – ACADIA Pharmaceuticals Inc. had its “buy” rating reiterated by analysts at Aegis Capital. They now have a USD 54 price target on the stock.

03/30/2016 – ACADIA Pharmaceuticals Inc. had its “buy” rating reiterated by analysts at Needham & Company. They now have a USD 49 price target on the stock.

03/28/2016 – ACADIA Pharmaceuticals Inc. had its “buy” rating reiterated by analysts at H.C. Wainwright. They now have a USD 50 price target on the stock.

03/21/2016 – ACADIA Pharmaceuticals Inc. had its “outperform” rating reiterated by analysts at JMP Securities. They now have a USD 43 price target on the stock.

02/24/2016 – ACADIA Pharmaceuticals Inc. had its “neutral” rating reiterated by analysts at JP Morgan. They now have a USD 61 price target on the stock.

02/08/2016 – Bank of America Merrill Lynch began new coverage on ACADIA Pharmaceuticals Inc. giving the company a “buy” rating. They now have a USD 40 price target on the stock.

05/12/2015 – ACADIA Pharmaceuticals Inc. was downgraded to “sell” by analysts at Zacks.

03/12/2015 – ACADIA Pharmaceuticals Inc. had its “buy” rating reiterated by analysts at Ladenburg Thalmann. They now have a USD 40 price target on the stock.

03/12/2015 – ACADIA Pharmaceuticals Inc. had its “buy” rating reiterated by analysts at Jefferies. They now have a USD 47 price target on the stock.

02/06/2015 – ACADIA Pharmaceuticals Inc. had its “buy” rating reiterated by analysts at Roth Capital. They now have a USD 42 price target on the stock.

10/07/2013 – Ned Davis Research began new coverage on ACADIA Pharmaceuticals Inc. giving the company a “neutral” rating.

The share price of ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD) was up +2.22% during the last day of trading, with a day high of 28.50. 2952182 shares were traded during the last session.

The stock’s 50 day moving average is 29.52 and its 200 day moving average is 28.86. The stock’s market capitalization is 2.80B. ACADIA Pharmaceuticals Inc. has a 52-week low of 16.64 and a 52-week high of 51.99.

View other investors thoughts on ACADIA Pharmaceuticals Inc. with our new Stock Talk discussion platform. Sign up for free to contribute to the community and view research provided from other investors for any stock listed on the LSE, NYSE or NASDAQ.